What is the fair value of Alvotech SA (NASDAQ-ALVO) stock?

The current fair value estimate for Alvotech SA (NASDAQ-ALVO) is $5.42. This implies an estimated downside of 7.6% versus the current market price.

Is Alvotech SA (NASDAQ-ALVO) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.6% versus the current market price.

What is the analyst price target for NASDAQ-ALVO stock?

The available analyst price target for Alvotech SA (NASDAQ-ALVO) is $6.80. The analyst target implies estimated upside of 15.8%.

How is the financial health of Alvotech SA?

The current financial health read for Alvotech SA (NASDAQ-ALVO) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Alvotech SA's next earnings date?

The next earnings date currently listed for Alvotech SA (NASDAQ-ALVO) is November 11, 2026.

Does Alvotech SA (NASDAQ-ALVO) pay dividends?

The latest available data indicates no current dividend yield for Alvotech SA (NASDAQ-ALVO).

What is the market capitalization of Alvotech SA?

The current market capitalization listed for Alvotech SA is 2.095 B.

What is the enterprise value of Alvotech SA?

The current enterprise value listed for Alvotech SA is 3.404 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Alvotech SA?

The ticker symbol for Alvotech SA is NASDAQ-ALVO, and the stock is listed on NASDAQ.

Where is Alvotech SA (NASDAQ-ALVO) listed?

Alvotech SA (NASDAQ-ALVO) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Alvotech SA?

The current debt-to-total-capital ratio listed for Alvotech SA is 40.9%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Alvotech SA?

The free float listed for Alvotech SA is 39.5%. Free float helps investors understand how much of the share base is available for public trading.

Alvotech SA (ALVO) Fair Value & Stock Analysis

Alvotech SA (ALVO)

Alvotech SA is a Luxembourg-based biotechnology company founded in 2013 and listed on NASDAQ under the ticker ALVO. Through its subsidiaries, the company develops and manufactures biosimilar medicines for patients in markets around the world. Its portfolio spans treatments in autoimmune disease, eye disorders, bone conditions, and cancer-related care. The company’s biosimilar programs include AVT02, AVT04, AVT05, AVT06, AVT16, AVT23, and AVT33. These candidates and products are designed to reference well-known biologic therapies such as Humira, Stelara, Eylea, Xgeva, Prolia, Simponi, Entyvio, Xolair, and Keytruda, with therapeutic uses covering inflammatory diseases, retinal conditions, bone loss, and selected oncology indications.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-ALVO	$5.42	-7.6% Downside	Fair	$6.80	15.8% Upside	Fair	Good	0.0%	November 11, 2026	4.2x	2.095 B	3.404 B	40.9%	39.5%	-1.3	145.5%